2[1]Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small-cell lung cancer[J]. Invest New Drugs,2000,18(1):29-42. 被引量：1
3[2]Merimsky O, Wigler N, Greif Y, et al. Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small-cell lung cancer: a phase Ⅱ study[J]. Anticancer Drugs,2000,11(2):117-121. 被引量：1
4[3]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2000,18(1):122-130. 被引量：1
5[4]Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,1999,17(1):12-18. 被引量：1
6[5]Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Project[J]. J Clin Oncol1999,17(11):3522-3530. 被引量：1
7[6]Schiller J, Harrington D, Sandler A, et al. A randomized phase III trial of fourchemotherapy regimens in advanced non-samll cell lung cancer (NSCLC)[J]. Am Soc Clin Oncol,2000,19:1-1. 被引量：1
8[7]Kroep JR, Peters GJ, van Moorsel CJA, et al. Gemcitabine-cisplatin: A schedule finding study[J]. Ann Oncol,1999,10(12):1503-1510. 被引量：1
9[8]Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer[J]. J Clin Oncol,1999,17(7):2190-2197. 被引量：1
10[9]Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung Cancer[J]. Ann Oncol1999,10(9):1043-1049. 被引量：1
4Anderson H,Lund B,Bach F. Single-agent activity of weekly gemcitabine in advanced non-smal-celllung cancer:a phase II study[J].{H}Journal of Clinical Oncology,1994,(09):1821-1826. 被引量：1
5Monnet I,Brienza S,Hugret F. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer(NSCLC)[J].{H}EUROPEAN JOURNAL OF CANCER,1998,(07):1124-1127. 被引量：1
6Bidoli P,Zilembo N,Cortinovis D. Randomized phase II three-arm trial with three platinum-based dou-blets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study[J].{H}ANNALS OF ONCOLOGY,2007,(03):461-467. 被引量：1
7Egger M,Smith GD,Schneider M. Bias in me-ta-analysis detected by a simple,graphical test[J].{H}British Medical Journal,1997,(7109):629-634. 被引量：1
8Louafi S,Boige V,Ducreux M. Gemcitabine plus oxaliplatin(GEMOX)in patients with advanced hepa-tocellular carcinoma(HCC)[J].{H}CANCER,2007,(07):1384-1390. 被引量：1
